

# Martina L Porter

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4664101/publications.pdf>

Version: 2024-02-01

41  
papers

476  
citations

840119

11  
h-index

752256

20  
g-index

43  
all docs

43  
docs citations

43  
times ranked

622  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Evaluation. , 2022, , 62-68.		0
2	Systemic nonbiologic treatments for hidradenitis suppurativa. <i>Dermatological Reviews</i> , 2022, 3, 70-97.	0.3	0
3	The Yin and Yang of Skin Microbiota in "Swimmer Acne". <i>Experimental Dermatology</i> , 2022, , .	1.4	4
4	Advances in biologic and small molecule therapies for hidradenitis suppurativa. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 959-978.	0.9	4
5	Dermatologic inflammatory conditions require high loading and maintenance doses of biologic therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	0
6	High-dose spironolactone for acne in patients with polycystic ovarian syndrome: A single-institution retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 740-741.	0.6	4
7	Psoriasis: Knowledge, attitudes and perceptions among primary care providers. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1421-1423.	0.6	3
8	Sunscreen recommendations for patients with skin of color in the popular press and in the dermatology clinic. <i>International Journal of Women's Dermatology</i> , 2021, 7, 165-170.	1.1	23
9	A visit guide for hidradenitis suppurativa"Managing a complex disease in a busy clinic. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e155-e160.	0.6	4
10	Quantifying Itch: Measurement on the Way to Management. , 2021, 107, 167-168.		0
11	A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1147-1161.	1.0	6
12	COVID-19 impacts on dermatologic surgery patients: A single institution experience. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1698-1699.	0.6	4
13	Response to Letter to the Editor entitled: Rethinking biologic and pregnancy research: The importance of assessing postpartum immunosuppression of the infant. <i>International Journal of Women's Dermatology</i> , 2021, 7, 510-511.	1.1	0
14	Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. <i>British Journal of Dermatology</i> , 2021, 185, 1072-1074.	1.4	5
15	Effects of swimming on facial sebum in adolescents. <i>Pediatric Dermatology</i> , 2021, , .	0.5	0
16	Nonmelanoma skin cancers are more likely to be untreated in elderly patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 505-507.	0.6	7
17	Re-evaluating the relationship between appointment nonattendance and appointment lead time. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, e97-e98.	0.6	1
18	Investigating race and gender in age at onset of hidradenitis suppurativa. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e139-e141.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1215-1218.	0.6	18
20	Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. <i>International Journal of Women's Dermatology</i> , 2020, 6, 159-163.	1.1	8
21	Biologic therapies for the treatment of hidradenitis suppurativa. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 621-633.	1.4	11
22	Publication trends in hidradenitis suppurativa from 2008 to 2018. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1885-1889.	1.3	13
23	Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. <i>JAAD Case Reports</i> , 2020, 6, 99-102.	0.4	39
24	Reply to: "Lack of a US Food and Drug Administration indication should not limit access to appropriate treatment". <i>Journal of the American Academy of Dermatology</i> , 2019, 81, e19-e20.	0.6	0
25	TNF- $\alpha$ inhibitors in the treatment of hidradenitis suppurativa. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231985164.	1.1	33
26	Biologic Treatment for Hidradenitis Suppurativa. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 625-638.	3.3	21
27	Use of biologics in pregnancy: limitations stemming from clinical trials and registry experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e276-e277.	1.3	2
28	Examining the prior authorization process, patient outcomes, and the impact of a pharmacy intervention: A single-center review. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1308-1318.	0.6	13
29	Longstanding alopecia and nail dystrophy are associated with more severe overall chronic graft-versus-host disease in adults. <i>Bone Marrow Transplantation</i> , 2019, 54, 469-472.	1.3	5
30	Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 114-119.	0.6	54
31	Online communications among hidradenitis suppurativa patients reflect community needs. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1760-1762.	0.6	12
32	Understanding patient engagement in psoriasis treatment. <i>British Journal of Dermatology</i> , 2018, 178, 988-989.	1.4	3
33	Pharmacoeconomics of Systemic and Biologic Therapy in Dermatology. , 2018, , 83-91.		1
34	Response to: Remission of hidradenitis suppurativa after bariatric surgery. <i>JAAD Case Reports</i> , 2018, 4, 278-279.	0.4	9
35	Predictions, Surprises, and the Future of the Dermatology Workforce. <i>JAMA Dermatology</i> , 2018, 154, 1253.	2.0	14
36	Assessment of treatment-seeking behaviour in patients with psoriasis. <i>British Journal of Dermatology</i> , 2018, 179, 989-990.	1.4	2

#	ARTICLE	IF	CITATIONS
37	Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 182-189.	1.6	13
38	Current guidelines for psoriasis treatment: a work in progress. <i>Cutis</i> , 2018, 101, 10-12.	0.4	30
39	Update on biologic safety for patients with psoriasis during pregnancy. <i>International Journal of Women's Dermatology</i> , 2017, 3, 21-25.	1.1	76
40	Comorbidities of hidradenitis suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 55-57.	1.6	22
41	Hidradenitis suppurativa scoring systems: can we choose just one?. <i>Cutis</i> , 2017, 99, 156-157.	0.4	3